Assessment of electrophysiologic testing

New York, June 30, 2000 (Praxis Press) Mortality rates from coronary artery disease (CAD), abnormal ventricular function and unsustained ventricular tachycardia are high. In patients with a history of myocardial infarction, cardiac arrest is often the result of reentrant ventricular tachycardia or fibrillation. Studies have not clearly assessed the prognostic value of electrophysiologic testing for these cases. In the Multicenter Unsustained Tachycardia Trial, Buxton et al performed electrophys

June 30, 2000

New York, June 30, 2000 (Praxis Press) Mortality rates from coronary artery disease (CAD), abnormal ventricular function and unsustained ventricular tachycardia are high. In patients with a history of myocardial infarction, cardiac arrest is often the result of reentrant ventricular tachycardia or fibrillation. Studies have not clearly assessed the prognostic value of electrophysiologic testing for these cases. In the Multicenter Unsustained Tachycardia Trial, Buxton et al performed electrophysiologic testing to group of such patients and randomly assigned patients with inducible tachyarrhythmias to either antiarrhythmic therapy guided by electrophysiologic testing or no therapy at all (see paper). The findings show that induction of sustained ventricular tachyarrhythmias by programmed stimulation identifies patients at greater risk of death from arrhythmia. In this study, the procedure had a negative predictive value of 88 percent for death due to arrhythmia within two years for patients without inducible arrhythmia. The value of this prognosis may diminish with time however, because of the progression of coronary disease and the ensuing formation of new circuits.

Popular Now

  1. UC Berkeley Receives CRISPR Patent in Europe
    Daily News UC Berkeley Receives CRISPR Patent in Europe

    The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.

  2. DNA Replication Errors Contribute to Cancer Risk
  3. Should Healthy People Have Their Exomes Sequenced?
    Daily News Should Healthy People Have Their Exomes Sequenced?

    With its announced launch of a whole-exome sequencing service for apparently healthy individuals, Ambry Genetics is the latest company to enter this growing market. But whether these services are useful for most people remains up for debate.  

  4. Rethinking a Cancer Drug Target
    Daily News Rethinking a Cancer Drug Target

    The results of a CRISPR-Cas9 study suggest that MELK—a protein thought to play a critical role in cancer—is not necessary for cancer cell survival.

Business Birmingham